List of Excipients in Branded Drug COPAXONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Neuroscience Inc	COPAXONE	glatiramer acetate	68546-317	MANNITOL

Copaxone Excipient Strategy and Commercial Opportunities in Glatiramer Acetate

Last updated: September 14, 2026

Copaxone is a subcutaneous glatiramer acetate product whose formulation is unusually simple: glatiramer acetate in water for injection with mannitol as the principal excipient. The commercial opportunity is therefore not a novel-excipient strategy. It is concentrated in manufacturing consistency, syringe and device performance, injection tolerability, supply reliability, and differentiated delivery formats.

Teva’s principal formulation advantages are the established 20 mg/mL once-daily and 40 mg/mL three-times-weekly regimens. Generic competition has eroded product exclusivity, but the complex synthetic polypeptide mixture, sterile injectable manufacturing requirements, and device economics continue to create barriers for new entrants. [1-4]

What excipients are used in Copaxone?

Copaxone contains glatiramer acetate, mannitol, and water for injection. The commercial formulations use the same basic excipient architecture.

Product	Strength	Administration	Key excipient	Approximate mannitol concentration
Copaxone	20 mg/mL	Subcutaneous once daily	Mannitol	40 mg/mL
Copaxone	40 mg/mL	Subcutaneous three times weekly	Mannitol	40 mg/mL

The solution is supplied in a prefilled syringe. The FDA label identifies mannitol as the inactive ingredient and specifies storage under refrigerated conditions, with limited room-temperature handling permitted under the labeled conditions. [1]

Mannitol performs several formulation functions:

• It adjusts tonicity for subcutaneous injection.
• It contributes to solution properties and injection comfort.
• It is compatible with the aqueous glatiramer acetate system.
• It is a well-established pharmaceutical excipient with broad regulatory acceptance.

Copaxone does not use a conventional preservative system in its single-use prefilled syringe presentation. That approach reduces preservative-related tolerability concerns and supports a sterile, unit-dose product.

Why is mannitol the central excipient in Copaxone?

Mannitol is commercially attractive because it is familiar to regulators, available from multiple suppliers, and supported by extensive pharmaceutical-use history. It is not, however, a strong standalone differentiation point.

For a glatiramer acetate injectable, the critical formulation risks are more likely to involve:

1. Polypeptide composition and molecular-weight distribution.
2. Batch-to-batch reproducibility.
3. Aggregation and particulate control.
4. Sterile filtration and aseptic filling.
5. Syringe compatibility.
6. Extractables and leachables.
7. Injection-force and device performance.

The excipient strategy must preserve the product’s physicochemical and immunologic comparability. A change from mannitol to another tonicity agent, such as sodium chloride or an alternative polyol, could alter osmolality, pH behavior, viscosity, aggregation, injection pain, and the active ingredient’s conformational or distribution profile.

For that reason, mannitol is strategically valuable less because it is proprietary than because it is a low-risk, established component of the reference formulation.

What formulation patents protect Copaxone?

The commercial protection of Copaxone historically relied more heavily on formulation, dosing, manufacturing, and method-of-use claims than on exclusivity for mannitol itself. Mannitol is a long-established excipient and generally cannot support meaningful exclusivity unless claimed in a narrow, novel combination with specific formulation or manufacturing parameters.

Copaxone-related patent strategies have included:

• Specific glatiramer acetate concentrations.
• Three-times-weekly dosing of the 40 mg/mL product.
• Stability and formulation characteristics.
• Manufacturing processes for the synthetic polypeptide mixture.
• Methods of treating multiple sclerosis.
• Product-by-process or characterization concepts directed to glatiramer acetate.

The relevant patent estate has been subject to extensive Paragraph IV litigation. Teva sued generic applicants after ANDA filings for glatiramer acetate products, including challenges involving 20 mg/mL and 40 mg/mL presentations. Several asserted patents were invalidated, narrowed, or avoided through litigation and settlement activity. [5-8]

A current freedom-to-operate analysis must distinguish:

Protection category	Commercial relevance
Active-ingredient composition claims	Limited if expired or vulnerable; glatiramer acetate is a complex mixture rather than a conventional small molecule
Formulation claims	Potentially relevant where concentration, excipient ratio, pH, or stability is narrowly claimed
Method-of-use claims	May affect labeling and skinny-label entry
Manufacturing claims	Can delay or complicate supply, even when product patents are weak
Device claims	May protect the prefilled syringe, autoinjector, or delivery system
Regulatory exclusivity	Historically important, but less durable than patent protection for mature Copaxone presentations

The Orange Book is the controlling source for current listed patents and FDA-approved labeling-related exclusivity. [2] Patent expiration should be verified by product, strength, formulation, and listed patent because Copaxone protection has changed through litigation, delisting, expiry, and settlement.

When did Copaxone lose exclusivity?

Copaxone’s principal small-molecule regulatory exclusivity periods have expired. FDA-approved generic glatiramer acetate products entered the U.S. market for both the 20 mg/mL and 40 mg/mL presentations.

Key milestones include:

Milestone	Date or period	Commercial effect
FDA approval of Copaxone 20 mg/mL	1996	Established the once-daily reference product
FDA approval of Copaxone 40 mg/mL	2014	Created the three-times-weekly higher-strength product
FDA approval of first generic glatiramer acetate 20 mg/mL	2015	Opened generic competition for the daily regimen
FDA approval of first generic glatiramer acetate 40 mg/mL	2017	Opened generic competition for the three-times-weekly regimen
Subsequent generic approvals	2017 onward	Increased pricing and formulary pressure

Sandoz’s Glatopa was approved as a generic version of Copaxone 20 mg/mL and later 40 mg/mL. FDA treated the products as therapeutically equivalent under the applicable regulatory pathway, although glatiramer acetate requires a more complex demonstration of sameness than a conventional single-molecule generic. [3,4]

What is the FDA and Orange Book status of Copaxone?

Copaxone is an FDA-approved prescription injectable for relapsing forms of multiple sclerosis. The active ingredient is glatiramer acetate, a synthetic polypeptide mixture composed of four amino acids.

FDA-approved presentations include:

• 20 mg/mL prefilled syringe administered once daily.
• 40 mg/mL prefilled syringe administered three times weekly, with at least 48 hours between doses.

The product is listed in the FDA Orange Book as a reference product against which approved generic glatiramer acetate products are evaluated. [1,2]

The primary regulatory distinction is that glatiramer acetate is not a conventional chemically defined small molecule. The active ingredient is a heterogeneous mixture. FDA’s product-specific guidance has therefore focused on analytical characterization, comparative physicochemical properties, and immunologic or functional evidence relevant to sameness. [4]

This complexity creates a regulatory barrier even when the excipient composition is simple.

Which companies are challenging Copaxone?

The main competitive pressure has come from generic manufacturers rather than biosimilar developers. Relevant companies have included:

• Sandoz, through Glatopa.
• Mylan, later part of Viatris.
• Other ANDA applicants seeking approval for glatiramer acetate injection.
• Contract manufacturers and specialty injectable suppliers supporting generic applicants.

Glatiramer acetate is regulated as a generic drug rather than as a biosimilar under the U.S. Public Health Service Act framework. Biosimilar terminology is therefore not the primary legal or commercial framework for Copaxone competition.

The competitive challenge is divided into two levels:

1. Regulatory sameness of the glatiramer acetate mixture.
2. Commercial substitution through payer formularies, specialty-pharmacy channels, and patient support programs.

The second factor is often more important than the excipient composition. A generic with the same active ingredient and an equivalent formulation can still face switching resistance because patients may value device familiarity, injection experience, and support services.

How strong is the Copaxone patent estate?

The remaining strength of the Copaxone estate is mixed.

Active ingredient

Glatiramer acetate itself is mature. Broad composition protection is not the principal barrier to entry for modern competitors.

Excipient formulation

Mannitol-based formulation claims may protect narrow combinations, but mannitol alone is unlikely to provide durable exclusivity. The strongest formulation positions would require a defined concentration, pH range, stability profile, or manufacturing parameter that produces a legally meaningful distinction.

Method of use

The 40 mg/mL three-times-weekly regimen created a commercially important differentiation from the original 20 mg/mL daily product. Method-of-use claims can remain relevant where they are valid, enforceable, and reflected in the reference product’s labeling.

Manufacturing

Manufacturing claims may have practical importance because glatiramer acetate is a complex mixture. A competitor can avoid a patent claim by using a different process, but the alternative process must still deliver a comparable product with acceptable batch consistency.

Device

The prefilled syringe and autoinjector ecosystem can create practical barriers that are not captured by active-ingredient patents. Device patents, combination-product considerations, human-factors requirements, and supplier qualification can affect launch timing.

Overall, Copaxone has a weaker broad exclusivity position than a newly launched specialty injectable but a more complex competitive environment than a typical small-molecule tablet.

What excipient strategies could create commercial opportunities?

1. Mannitol supply and quality specialization

Mannitol is a commodity excipient, but pharmaceutical-grade supply can be differentiated through:

• Low bioburden and endotoxin control.
• Tight particle and moisture specifications.
• Reliable global supply.
• Documentation for change control and regulatory filings.
• Compatibility data with glatiramer acetate.

A supplier would have limited leverage if it sells only standard mannitol. Greater value comes from qualified, validated supply supported by formulation-specific compatibility data.

2. Alternative tonicity systems

A company could investigate sodium chloride, sorbitol, trehalose, or other polyols. The regulatory and technical burden would be substantial. Any replacement would require evidence that the change does not affect:

• Osmolality.
• Injection-site tolerability.
• Polypeptide aggregation.
• Particulate formation.
• Stability over the labeled shelf life.
• Immunologic performance.
• Syringe and stopper compatibility.

This opportunity is more suitable for a lifecycle-management program than for a low-cost generic strategy.

3. Reduced-injection delivery

The 40 mg/mL product already reduces injection frequency from seven injections per week to three. Further commercial opportunities could involve:

• Autoinjectors with lower injection force.
• Hidden-needle systems.
• Electronic adherence monitoring.
• Prefilled cartridges.
• Longer-interval formulations, if technically and clinically feasible.
• Combination delivery systems that simplify handling.

These products would need to demonstrate practical patient benefit, not merely a new excipient composition.

4. Injection-site tolerability

Excipient changes may support a tolerability strategy if they reduce pain, erythema, induration, or post-injection discomfort. The evidence burden is high because injection-site reactions are also influenced by:

• Needle gauge and length.
• Injection volume.
• Temperature.
• Injection speed.
• Device mechanics.
• Storage conditions.
• Patient technique.

A successful product would likely require coordinated formulation and device development.

5. Stability and distribution

Copaxone’s refrigerated storage requirements create opportunities for improved logistics. A formulation with greater room-temperature stability could reduce cold-chain costs and improve patient convenience. The development target would need to address:

• Aggregation during temperature excursions.
• Freeze-thaw exposure.
• Light sensitivity.
• Container-closure integrity.
• Shipping stress.
• Shelf-life extension.

A stability improvement could be commercially meaningful even without changing the active ingredient.

What generic launch risks exist for glatiramer acetate?

Generic launch risk is higher than for a standard tablet because the product combines a complex active mixture with sterile injectable manufacturing and patient-facing delivery hardware.

Risk	Effect on launch
Active-mixture comparability	May increase analytical and regulatory requirements
Sterile manufacturing	Raises capital and quality-system requirements
Device compatibility	Can delay approval or create post-approval obligations
Patent litigation	May require a Paragraph IV defense or settlement
Payer contracting	Can determine actual uptake after approval
Patient switching	May slow substitution despite therapeutic equivalence
Supply reliability	Creates vulnerability in specialty-pharmacy distribution
Injection-site differences	Can affect persistence and prescriber acceptance

A generic applicant may obtain FDA approval but still achieve limited commercial penetration if the reference product retains favorable formulary placement, patient support, or device preference.

How does Copaxone compare with other multiple sclerosis injectables?

Copaxone competes with interferon beta products and, increasingly, oral and infusion therapies. Its main formulation advantage is the absence of a complex biologic protein manufacturing process associated with interferon products. Its main disadvantage is the continuing burden of frequent subcutaneous injections.

Product class	Formulation profile	Administration burden	Key commercial issue
Glatiramer acetate	Simple aqueous injectable with mannitol	Daily or three times weekly	Generic erosion and injection-site reactions
Interferon beta	Recombinant protein injectable	Weekly to several times weekly	Flu-like effects, immunogenicity, device competition
Oral disease-modifying therapies	Solid oral dosage forms	Daily or periodic dosing	Safety monitoring and systemic adverse effects
Infused therapies	Sterile biologic infusion	Infrequent administration	Administration infrastructure and safety risk

Copaxone remains most defensible where prescribers and patients prioritize a long clinical history, an established safety profile, and a non-interferon injectable option.

What licensing opportunities exist around Copaxone excipients?

Direct licensing of mannitol technology is unlikely to produce significant value unless paired with a broader platform. More credible opportunities include:

• Formulation patents covering improved stability.
• Device licensing for autoinjectors.
• Contract development and manufacturing of sterile glatiramer acetate.
• Analytical methods for active-mixture characterization.
• Container-closure systems with improved extractables profiles.
• Cold-chain reduction technologies.
• Specialty-pharmacy adherence platforms.

The strongest licensing asset would combine formulation, device, and manufacturing know-how. A single alternative excipient is less likely to command meaningful commercial terms.

Key Takeaways

• Copaxone uses a simple excipient system centered on mannitol and water for injection.
• Mannitol is strategically useful for tonicity and formulation familiarity but is not, by itself, a strong exclusivity asset.
• The main technical barriers are glatiramer acetate mixture control, sterile manufacturing, stability, and device performance.
• Generic glatiramer acetate products have entered the U.S. market for both 20 mg/mL and 40 mg/mL strengths.
• Copaxone’s strongest remaining commercial defenses are product experience, device integration, patient support, manufacturing know-how, and selected formulation or method-of-use rights.
• The most credible commercial opportunities involve improved stability, lower injection burden, device differentiation, and qualified pharmaceutical-grade supply rather than a standalone new excipient.
• Glatiramer acetate is regulated as a generic drug, not primarily through the biosimilar pathway.

FAQs About Copaxone Excipient and Commercial Strategy

Is mannitol in generic glatiramer acetate products?

Many generic products use a formulation comparable to the reference product, including mannitol. The precise inactive-ingredient profile should be confirmed in the FDA-approved labeling for each product.

Can a company patent mannitol in a Copaxone formulation?

Mannitol alone is unlikely to support meaningful new exclusivity. A patent would need to claim a novel and non-obvious formulation, stability profile, manufacturing condition, or functional result.

Does Copaxone require a biosimilar application?

No. Glatiramer acetate products are generally reviewed through the generic-drug framework rather than the biosimilar pathway.

What is the largest commercial weakness of Copaxone?

The principal weakness is frequent subcutaneous administration in a market with oral and infrequently administered multiple sclerosis therapies, combined with generic price competition.

Could a room-temperature Copaxone formulation be commercially valuable?

Yes. Extended room-temperature stability could reduce distribution costs, improve patient convenience, and support lifecycle differentiation, provided the formulation maintains active-mixture integrity, sterility, stability, and clinical performance.

References

1. U.S. Food and Drug Administration. (2023). Copaxone (glatiramer acetate injection) prescribing information. Teva Pharmaceuticals USA, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2015). FDA approves first generic glatiramer acetate to treat multiple sclerosis. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2017). Glatiramer acetate injection: Draft product-specific guidance. https://www.fda.gov/

5. U.S. Court of Appeals for the Federal Circuit. (2019). Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., patent litigation decisions concerning glatiramer acetate.

6. U.S. District Court for the District of Delaware. (2017-2020). Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc. and related glatiramer acetate patent litigation.

7. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for glatiramer acetate-related patents. https://patentcenter.uspto.gov/

8. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs, glatiramer acetate products. https://www.accessdata.fda.gov/scripts/cder/daf/